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Abstract: Mild cognitive impairment (MCI) (amnestic or non-amnestic) has different clinical and
neuropsychological characteristics, and its evolution is heterogeneous. Cardiovascular risk factors
(CVRF), such as hypertension, diabetes, or dyslipidemia, and the presence of the Apolipoprotein E
ε4 (ApoE ε4) polymorphism have been associated with an increased risk of developing Alzheimer’s
disease (AD) and other dementias but the relationship is inconsistent worldwide. We aimed to
establish the association between the ApoE ε4 carrier status and CVRF on MCI subtypes (amnestic
and non-amnestic) in Mexican older adults. Cross-sectional study including 137 older adults (n = 63
with normal cognition (NC), n = 24 with amnesic, and n = 50 with non-amnesic MCI). Multinomial
logistic regression models were performed in order to determine the association between ApoE ε4
polymorphism carrier and CVRF on amnestic and non-amnestic-MCI. ApoE ε4 carrier status was
present in 28.8% participants. The models showed that ApoE ε4 carrier status was not associated
neither aMCI nor naMCI condition. The interaction term ApoE ε4 × CVRF was not statistically
significant for both types of MCI. However, CVRF were associated with both types of MCI and the
association remained statistically significant after adjustment by sex, age, and education level. The
carrier status of the ApoE genotype does not contribute to this risk.
Keywords: apolipoprotein E ε4; cardiovascular risk factors; amnestic MCI; non-amnestic MCI;
Mexican Mestizo older adults
1. Introduction
The spectrum of cognitive impairment in older adults ranges from normal cognitive
status, cognitive complaint with normal screening test, mild cognitive impairment (MCI)
to dementia [1].
MCI, refers to the intermediate stage between the expected cognitive decline, associ-
ated with normal aging and dementia, which has gained a lot of interest. MCI represents a
damage of cognitive skills, revealed by neuropsychological tests—with global cognitive
functions and preserved everyday activities [2], which confers a higher risk of conversion
to dementia, particularly the amnestic MCI subtype Alzheimer´s dementia [3–5]. The
MCI prevalence among older adults ranges from 3.1% to 37.5% according to the criteria
used [6], which has made it difficult to establish its real frequency. In general, there are
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two subtypes of MCI: amnestic (aMCI), and non-amnestic (naMCI), each with specific
neuropsychological characteristics, and which in turn, are subdivided into single- and
multi-domain subtypes [7].
On the other hand, apolipoprotein E ε 4 (ApoE ε4) carrier status homozygous and
heterozygous is the most important genetic risk factor both AD and MCI, while the other
two isoforms (ε2 and ε3) of the gene are protective [8,9]. However, the association between
ApoE ε4 and the risk of AD does not seem to be universal. Population-based studies
have shown a weak association between the ApoE ε4 polymorphism and AD among
African-Americans, (ε4/ε4, OR: 5.7, 95% CI: 2.3–14.1) and Hispanic (ε4/ε4, OR: 2.2, 95%
CI: 0.7–6.7) populations, compared with Japanese (ε4/ε4, OR: 33.1, 95% CI: 13.6–80.5) and
non-Hispanic persons (ε4/ε4, OR: 12.5, 95% CI: 8.8–17.7) [10]. The presence of ApoE ε4
polymorphism combines synergistically with atherosclerosis, peripheral vascular disease
or diabetes, which all contribute to an increased risk of cognitive decline, particularly
AD [10]. In the same vein, ε4 allele has also been associated with increased susceptibility
to vascular dementia, cerebral amyloid angiopathy (CAA), and cognitive decline during
normal aging. In this way, ApoE ε4 is a risk factor for cardiovascular disease suggesting
an interaction with cerebrovascular disease, which in turn, has a harmful effect on the
cognitive function [9].
However, the association between ApoE ε4 polymorphism and the presence of cog-
nitive impairment has been inconsistent in various populations around the world and
whether the cause-effect association of the presence of CVRF and MCI is modulated by
the ApoE ε4 polymorphism is also unclear. Therefore, the objective of this study was to
establish the association between the ApoE ε4 carrier status and CVRF on MCI subtypes
(amnestic and non-amnestic), as well as to determine if there is a modification of the effect
due to the presence of CVRF and Apo E ε4 carrier status among Mexican older adults.
2. Materials and Methods
Cross-sectional study conducted at a Memory Clinic in a tertiary level University
Hospital in Mexico City, between March 2018 and February 2020. All procedures were
carried out only after written informed consent was obtained from the participants. The
study was approved by the Institutional Ethics Research Committee (GER-2416-17-19).
2.1. Participants
Eligible participants were adults aged 60 or older, ambulatory, as well as mestizo-
Mexicans. They underwent a comprehensive geriatric assessment by trained staff using
standardized methods, and a neuropsychological evaluation was conducted by an ex-
pert neuropsychologist. Exclusion criteria included uncontrolled or untreated depressive
symptoms ≥ 6 of the score of 15-items (Geriatric Depression Scale) (GDS) [11], delirium
or previous diagnosis of dementia, visual or hearing impairment, illiterates, uncontrolled
hypertension, untreated thyroid disease, high blood levels of glycated hemoglobin (≥9%),
presence of severe heart failure, and recent traumatic brain injury. Magnetic resonance
imaging was obtained for all participants using a standard protocol. Images were obtained
with a 1.5 T resonator (Siemens® Medical Systems, Waukesha, Wisconsin, USA), including
whole-brain T1-weighted, T2-weighted, FLAIR, and T2*-weighted gradient-recalled echo.
The MRI results were used by the researchers to rule out structural pathology that excluded
the patient from the study and to classify MCI subtypes.
Participants with aMCI, and naMCI subtype, and normal cognition (NC) were in-
cluded. Diagnosis was established according to Petersen’s criteria [12,13]. The Petersen
criteria include subjective memory complaint, corroborated by an informant, together with
preserved everyday activities, a memory impairment based on a standard neuropsycholog-
ical test, preserved global cognitive functions, and finally the exclusion of dementia [13].
The neuropsychologist evaluated the cognitive profiles through the following neu-
ropsychological battery: Mini-Mental State Examination (MMSE) [14], Montreal Cognitive
Assessment (MoCA) [15] and NEUROPSI (Brief Neuropsychological Evaluation in Span-
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ish), a standardized neuropsychological test for the Mexican population [16]. This test
succinctly assesses a broad spectrum of cognitive domains, including orientation, attention
and concentration, language, memory, visuospatial skills, and executive functions. Norma-
tive data for grading the test stem, from validation performed in Mexicans, and is adjusted
according to age, and educational level. The NEUROPSI has shown an appropriate test
re-test reliability as well as substantial interrater agreement. A composite score of 1.5 stan-
dard deviations (SD) below the adjusted mean for age and education was considered
as MCI. According to the evaluation, due to the sample size, it was decided to classify
MCI into two predominant profiles: aMCI: (1) amnestic (memory impairment only and
amnestic multidomain), or naMCI: (2) non-amnestic (single nonmemory cognitive domain
and multidomain impaired). The applied criteria are based on the recommendations of the
National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines
for Alzheimer’s disease [17].
The Katz index for activities of daily living (ADL) [18] and the Lawton Index for
instrumental activities of daily living (IADL) were used for the assessment of functional
status [19]. A participant was considered dependent for ADL when the score was ≤5/6;
whereas a subject was considered dependent for IADL when the Lawton’ score was ≤7/8
for women and ≤4/5 for men, respectively.
The differentiation between MCI and NC was considered if participants denied having
a memory complaint and had a normal cognitive performance to the battery of standardized
neuropsychological tests, according to age, sex, and educational level.
2.2. ApoE Genotype Determination Method
The ApoE genotype was determined with the use of a polymerase chain reaction (PCR).
10 mL of peripheral blood was obtained, subsequently, and following the real time PCR usual
method, DNA was extracted from leukocytes and later was amplified using oligonucleotide F4
(5′-ACAGAATTCGCCCCGGCCTGGTAcACAC-3′) and F6 (5′-lAAGCITGGCACGGCTGn =
cAAG). Each reaction mixture was heated at 95 ◦C for 5 min for denaturation and subjected
to 30 cycles for amplification, obtaining approximately 300 ng of amplified ApoE sequences.
Subsequently, 5 units of Hal (New England Biolabs, Ipswich, MA, USA) were added for
the digestion of the ApoE sequences. Each result was combined with polyacrylamide to
perform electrophoresis, obtaining the different genotypes: ε2 ε2/ε2 ε3/ε3 ε3/ε3 ε4/ε4
ε4/ε4 ε2 [18]. For the present study, the genotype was operationalized as a binomial
variable: those with 1 or more ApoE ε4 allele versus no ApoE ε4 allele.
2.3. Exposure Variable
Regarding the clinical assessment, in the clinical evaluation, some questions were
asked about the presence and/or absence of the following conditions, related to the car-
diovascular risks, which included: hypertension, current smoking status, obesity, hy-
pothyroidism, dyslipidemia, diabetes, coronary heart disease (CHD), and history of stroke.
Furthermore, the eight cardiovascular comorbidities were added to construct a variable for
cardiovascular risk factors CVRF
2.4. Covariates
Socio-demographic variables included sex, age and educational level as continuous
(years of age and education).
2.5. Statistical Analysis
To calculate the minimum sample size of people over the age of 60 years necessary
in this study to provide a valid estimate of the prevalence of MCI of 9%, a type I error of
0.05 and a power of 80% was assumed. Estimating that at least 36 patients per group were
necessary to find the statistical power.
Variables were described using arithmetic means and standard deviations (SD) or
frequency, and proportion, when appropriate. We used chi-square tests to compare categor-
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ical data and analysis of variance (ANOVA) for continuous variable. Post hoc Bonferroni
analysis were used to identify intra-group differences. In addition, to determine the associ-
ation, on the one hand, between the ApoE ε4 carrier status and, on the other, of the CVRF
with aMCI, naMCI, multinomial logistic regression models were constructed, adjusting for
potential confounders, including age, sex, and years of education. The interaction between
ApoE ε4 and CVRF was analyzed to test the modifying effect on the dependent variable.
Odds Ratio (OR) were estimated. A p-value < 0.05 was considered statistically significant,
and 95% confidence interval (CI) were provided. All statistical analyses were performed
using a SPSS version 22 for Windows® (Chicago, IL, USA).
3. Results
A total of 137 participants were allocated in three different subgroups: NC (n = 63),
aMCI (n = 24), and naMCI (n = 50). The mean age was 71 years (±7.2), 72.3% were female
and the mean educational years were 12.7 years (±5.04). Mean of MMSE was 27.8 (±1.9)
while, 24.1 (±3.6) and 101.5 (±13.9) for the MoCA and Neuropsi test, respectively. Hyper-
tension was the most frequent CVRF (57%), followed by dyslipidemia (39.4%), and diabetes
(25.8%). The mean of CVRF was 1.9 (±1.4). Apo E carrier status were ε2/ε2 homozygous
none, ε2/ε3 2 (0.7%), and ε3/ε3 homozygous 98 (71.8%), whereas ε3/ε4 heterozygous
36 (26.2%) and ε4/ε4 homozygous 3 (2.1%).
Table 1 presents the comparative analysis of sociodemographic and health-related
characteristics according to neurocognitive status. As expected, the NC group was younger
(p < 0.001), had more years of education (p < 0.001) and had better cognitive performance.
There were statistically significant differences between the aMCI and naMCI in depressive
symptoms by GDS scale (3.6 vs. 2.5 p < 0.005). The CVRF mean were higher in the aMCI
2.5 (±1.5) between NC and aMCI and naMCI group (p < 0.004).
Table 1. Sociodemographic and health characteristics, cognitive performance scores, cardiovascular risk factors, and ApoE














Age, years a,b,c 71.6 (7.23) 71.3 (6.2) 78.2 (7.4) 74.2 (7.2) <0.001
Female 99 (72.3) 53 (84.1%) 15 (62.5%) 31 (62%) 0.017
Education, years a,c 12.7 (5.04) 13.7 (3.7) 9.6 (5.9) 12.6 (5.6) 0.005
ABVD 5.8 (0.36) 5.8 (0.4) 5.9 (0.2) 5.9 (0.2) 0.150
AIVD 7.5 (1.06) 7.61 (1.0) 7.59 (1) 7.35 (1.0) 0.416
MMSE a,b 27.8 (1.9) 28.6(1.4) 26.5 (2.1) 27.3 (1.9) <0.001
MoCA a,b 24.1 (3.6) 26.1 (2.5) 21.8 (3.3) 22.1 (3.7) <0.001
NEUROPSI a,b,c 101.5 (13.94) 110.8 (9.04) 85.2 (11.3) 98.1 (9.41) <0.001
GDS a,c 2.3 (2.2) 1.83(1.76) 3.6(2.42) 2.5 (2.53) 0.005
Cardiovascular Risk Factors
Smoking status n (%) 59 (43%) 30 (48%) 7 (32%) 22 (45%) 0.433
Hypertension n (%) 78 (57%) 34 (54%) 13 (59%) 31 (66%) 0.449
Dyslipidemia n (%) 54 (39.4%) 19 (30%) 14 (64%) 21 (45%) 0.018
Diabetes n (%) 34 (25.8%) 12 (19%) 5 (23%) 17 (36%) 0.119
Obesity n (%) 36 (27.2%) 14 (22%) 5 (23%) 17 (35%) 0.299
Hypothyroidism n (%) 34 (24.8%) 11 (18%) 8 (36%) 15 (32%) 0.051
Stroke n (%) 10 (7.3%) 1 (2%) 5 (9%) 4 (23%) <0.001
CHD n (%) 12 (8.7%) 4 (6%) 5 (6%) 3 (18%) 0.051
CVRF mean(SD) a,b 1.9 (1.4) 1.5 (1.5) 2.5 (1.5) 2.2 (1.5) 0.004
















ε2/ε3 n (%) 0 (0%) 0 (0%) 1 (2%)
ε3/ε3 n (%) 48 (76%) 19 (79%) 30 (60%)
ε3/ε4 n (%) 14 (22%) 4 (17%) 18 (36%)
ε4/ε4 n (%) 1 (2%) 1 (4%) 1 (2%)
NC, normal cognition; aMCI, amnestic mild cognitive impairment, naMCI, non-amnestic mild cognitive impairment, Katz, Index of
Independence in Activities of Daily Living; Lawton, Index of Instrumental Activities of Daily Living; MMSE: Minimental Examination Test,
MoCA: Montreal Cognitive Assessment; NEUROPSI, brief Neuropsychological Evaluation in Spanish; GDS, Geriatric Depression Scale;
CHD, coronary heart disease; CVRF, cardiovascular disease risk factors. Post Hoc Analysis; significant difference < 0.05 was found between
a the NC and aMCI group, b NC and naMCI group, c aMCI and naMCI groups.
Table 2 shows the univariate multinomial logistic regression due to the effect of ApoE
ε4 carrier status in the three groups. Compared to the NC group, those with aMCI or naMCI
were older and had more CVRF. Education has an inverse association both aMCI (p < 0.002),
naMCI (p < 0.001) in comparison with the NC. Depressive symptoms were only associated
with aMCI subgroup (p < 0.002). Regarding cognitive performance compared to NC, both
aMCI had lower NEUROPSI test scores globally and in the domains of concentration and
attention, memory, language, and executive functions.
Table 2. Univariate multinomial logistic regression analysis of clinical and socio-demographic
characteristics among ApoE ε4 carrier status on amnestic and non -amnestic versus NC (n = 39).
aMCI naMCI
Odds Ratio 95% (CI) p Odds Ratio 95% CI p
Age 1.16 (1.07–1.25) <0.001 1.06 (1.01–1.13) 0.022
Female 2.6 (.29–23.85) 0.380 3.60 (.76–17.00) 0.106
Education 0.82 (.72–0.92) 0.002 0.95 (0.88–1.04) <0.001
GDS 1.52 (1.17–1.99) 0.002 1.16 (0.96–1.40) 0.119
CVRF 1.70 (1.18–2.46) <0.001 1.48 (1.10–1.00) 0.007
NEUROPSI:
Concentration and attention 0.70 (0.60–0.83) <0.001 0.80 (0.71–0.90) <0.001
Memory 0.67 (0.57–0.80) <0.001 0.77 (0.69–0.86) <0.001
Language 0.33 (0.20–0.55) <0.001 0.75 (0.58–0.98) 0.035
Executives functions 0.76 (0.60–0.83) <0.001 0.96 (0.71–0.90) <0.001
CI: confidence interval, NC: normal cognition, aMCI: amnestic mild cognitive impairment. naMCI: non-amnestic
mild cognitive impairment, GDS: Geriatric Depression Scale, CVRF: Cardiovascular Risk Factors, NEUROPSI:
Brief Neuropsychological Evaluation in Spanish.
The multinomial logistic regression model of cognitive function is showed in the
Table 3. The unadjusted model did not show a statistically significant association between
being ApoE ε4 carrier status and the presence of any type of MCI. On the contrary, there was
a statistically significant association between the presence of CVRF and aMCI (p = 0.004)
as well as naMCI (p = 0.009). This association remained statistically significant even after
adjusting for age, sex, and education. Finally, the interaction term ApoE ε4 and CVRF was
not statistically significant for both types of MCI.
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Table 3. Multiple Regression effect of the ApoE ε4carrier status on the NC, amnestic and non-amnestic MCI groups.
A. Unadjusted Model
aMCI naMCI
Odds Ratio (95% CI) p Odss Ratio (95% CI) p
















p = 0.004 *
1.7
(1.13–2.65)






p = 0.049 *










Odds Ratio (95% CI) p Odds Ratio (95% CI) p
















p = 0.018 *
1.62
(0.99–2.64)















NC, normal cognition; aMCI, amnestic mild cognitive impairment, naMCI, non-amnestic mild cognitive impairment. CVRF: Cardiovascular
Risk Factors. Adjusted Model for age, educational level and sex. ApoE ε3/ ε4 and ε4/ε4 and carrier status*CVRF: interaction. CI:
confidence interval. * p ≤ 0.05.
4. Discussion
MCI amnestic or non-amnestic has different clinical and neuropsychological charac-
teristics, and its trajectory is heterogeneous. Our study shows that the presence of factors,
such as older age, low education, cardiovascular risk factors, and depression, are associated
with aMCI and naMCI independently of the APOE e4 allele carrier status.
Genis et al., in a study that included 297 Mexicans with an unidentified cognitive dis-
order demonstrated that the ApoE ε4 genotype increased the risk of cognitive impairment
by approximately 6% [20]. Juárez-Cedillo et al. demonstrated, in a study in a Mexican
population that aimed to assess the prevalence of MCI in the Mexican population and
that included 2944 subjects, that advanced age was strongly associated with the risk of
MCI; with a (OR, 2.09; 95% CI, 1.44–2.94, p < 0.001) for the group between 71–84 years,
and (OR, 5.13; 95% CI, 3.49–7.61, p < 0.001) in those older than 85 years. [5] Other study
conducted among 175 Mexican older adults that evaluated the associated factors with the
progression of MCI to dementia, showed older age as a risk factor to dementia (HR, 4.95;
95% CI, 1.96–12.46; p < 0.001) [21].
Another risk factor for developing MCI is low educational level. A study that evalu-
ated the risk factors in Mexican-Americans to develop cognitive impairment, showed that
the protective effect of the educational level offers a reduction in the prevalence only that
those with more than 13 years of schooling, while lower levels increased the risk [22]. The
effects of the years of education are based on the concepts of cognitive and brain reserve,
in addition to the maintenance of cognitive reserve throughout life [23].
Among the cardiovascular factors previously linked to dementia and MCI, diabetes
is the most associated risk factor for cognitive impairment in the Mexican population.
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Luchsinger et al. demonstrated, in a longitudinal cohort study that included 1772 partici-
pants, that diabetes was significantly associated with an increased risk, compared to all
the different types of MCI (HR, 1.4; 95% CI, 1.1–1.8) after adjusting diverse variables, such
as: age, sex, ethnic group, schooling level, APOEε4, hypertension, low-density lipoprotein
level, heart disease, cerebrovascular disease, and smoking [24]. The Singapore Longitudinal
Aging Study Cohort also demonstrated an association between older age an increase in the
incidence of MCI (HR, 2.84; 95% CI, 1.92–4.19) [25].
Another of the linked factors has been hypertension: a systematic review, which
included fourteen studies (n = 96,158) and which evaluated the association between the
decrease in blood pressure and the cognitive prognosis during 49.2 months, showed that
those patients with antihypertensive treatment had a reduction in the risk from dementia or
MCI (12 trials; 92,135 participants) (7.0% vs. 7.5% of patients over a mean trial follow-up of
4.1 years; (OR, 0.93; 95% CI, 0.88–0.98); absolute risk reduction (OR, 0.3; 95% CI, 0.09–0.68),
and cognitive decline (8 trials) (20.2% vs. 21.1% of participants over a mean trial follow-up
of 4.1 years (OR, 0.93; 95 % CI, 0.88–0.99); absolute risk reduction, (0.71%, 95% CI, 0.19–1.2%)
concluding that the decrease in blood pressure in the group with antihypertensive treatment
was associated with a lower risk of incidence of dementia or cognitive impairment [26].
Similarly, the SPRINT-MIND study demonstrated that intensive blood pressure treatment
(<120 mmHg systolic) reduced the risk of MCI (14.6 vs. 18.3 × 1000 people/year, (HR,
0.81; 95% CI, 0.69–0.95), emphasizing the importance of Blood Pressure control at this
stage [27]. The mechanism by which hypertension produces alteration in cognitive function
is through inducing atherosclerosis, remodeling, hypertrophy of large arteries, presence
of microateromas and lipohyalinosis in small vessels, which leads to vascular damage,
chronic hypoxia, and brain atrophy [28].
Regarding dyslipidemia, some studies evaluated the effect of this disease and the risk
of developing MCI. Hashem HA et al., demonstrated in a study that included 158 adults
over 65 years of age, that dyslipidemia (hypertriglyceridemia) was associated with the risk
of developing MCI, compared to patients with lower levels (p < 0.001) [29]. Tze Ping et al.
demonstrated in the Singapore Longitudinal Aging Study Cohort, which included 1519
participants, that dyslipidemia was associated with an increase in the incidence of MCI
(HR, 1.48; 95% CI, 1.01–2.15) [25].
The mechanisms by which dyslipidemia favors neurodegeneration and vascular
damage, seem to initiate extracellular accumulation of amyloid beta protein, alteration of
synaptic connections, as well as increased oxidative stress in the hippocampus [30,31].
On the other hand, the association between depression and cognitive impairment is
overwhelming. A meta-analysis study which included (n = 20,892) and whose objective was
to know the prevalence of depression in patients with MCI, reported an overall prevalence
of 32% in patients with MCI (95% CI, 27–37%) and 40% (95% CI, 32–48%), in clinical trials,
showing that depression in this group of patients is high [32]. The mechanism by which
depression is considered a risk factor is due to its association with producing atrophy
in affected regions in AD. In addition, it can be related to neuropathological changes, so
it could be potentially useful as a marker to identify MCI patients at risk of developing
dementia [33].
The impact of these factors has been recently published by the Lancet Commis-
sion, which considers hypertension, obesity, hearing loss, head trauma, and excessive
alcohol consumption in the middle stage of life as risk factors for cognitive impairment
(45–65 years); and diabetes, smoking, depression, social isolation, diabetes mellitus, air
pollution, and physical inactivity in the advanced stage of life (>65 years), for which it is
proposed that by controlling each of these risk factors, the prevalence of dementia could be
reduced, based on the fraction of risk attributable to the population [34].
Another important outcome in our study is the carrier of the ApoE ε4 allele status,
which was not associated with the MCI condition, despite the evidence of its association.
As a risk factor for cognitive decline and neurodegeneration, there is still controversy
regarding this association in the Mexican population [35]. These findings are in line with
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those of Villalpando et al., who reported a low prevalence of the ε4 allele in Mexican older
adults. Furthermore, these authors did not demonstrate association between the ε4 allele
and Alzheimer’s Disease (OR: 1.15, 95% CI: 0.54–2.47. p = 0.123) [36]. González et al., in
a study that included 6377 Hispanic/Latinos, with a range age between 50 and 86 years,
and MCI diagnosis did not demonstrate an association with both the ApoE ε4 or ApoE
ε2 genotype, suggesting that the etiology of MCI could be different between Africans
and Latinos, with an Amerindian mix vs. people with European ancestry, possibly as a
result of colonizers in southern Europe, having a lower ApoE ε4 prevalence compared
to northern Europeans. ApoE genotypes in Mexican-Americans, Mexican Mestizos and
Mayans, showed a higher frequency of the ε3 allele (89–92%) and a lower one for the ε4
(6.9 to 8.4%), and ε2 (lower or absent) alleles [37].
This study has several limitations that must be recognized; cross-sectional design, and
the small size and low statistical power of the sample to detect the influence of APOE ε4 as
an association factor of aMCI and naMCI or to determine a dose-response effect between
heterozygotes and homozygotes was not possible. In addition, we did not include other
genetic polymorphisms that could be helpful in determining the effect of the genotype,
and its respective alleles, over Mexican population with MCI. However, the main strength
of our study is that currently there are not enough Latin American or Mexican studies that
analyze the association between the ApoE genotype and cardiovascular risk factors and
their potential interaction in two different forms of MCI.
5. Conclusions
Our study shows that cardiovascular risk factors represent the main associated factors
for aMCI and naMCI after controlling for possible confounding factors. On the other hand,
despite the fact that multiple studies in various ethnic groups (European) have shown
that the APOE genotype is a risk factor for MCI, in the mestizo population the carrier
status of the APOE ε4 allele did not contribute to this risk. However, more studies in the
mestizo population are necessary to know the role of this or other polymorphisms and its
relationship with MCI, since this could support the establishment of future strategies in
the diagnosis and treatment of this disease in the mestizo population.
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